We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current SBTX market cap is 563.5M. The company's latest EPS is USD -0.5663 and P/E is -22.18.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 500k | 2.07M |
| Operating Income | -17.98M | -10.23M | -13.19M | -15.34M | -21.75M |
| Net Income | -14.87M | -7.17M | -10.29M | -12.52M | -19.13M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 1.32M | 30k |
| Operating Income | -24.07M | -32.92M | -89.58M | -35.52M | -67.52M |
| Net Income | -23.97M | -32.95M | -89.48M | -34.68M | -54.37M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 248.56M | 233.19M | 227.58M | 221.97M | 217.6M |
| Total Liabilities | 11.27M | 2.43M | 3.72M | 6.73M | 16.62M |
| Total Equity | 237.28M | 230.76M | 223.87M | 215.24M | 200.98M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 15.65M | 394.8M | 333.47M | 281.44M | 233.19M |
| Total Liabilities | 21.25M | 11.93M | 19.65M | 8.55M | 2.43M |
| Total Equity | -58.78M | 382.88M | 313.82M | 272.89M | 230.76M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -41.86M | -59.27M | -6.71M | -13.99M | -28.46M |
| Investing | -113.22M | -87.18M | -8.51M | -21.16M | -4.34M |
| Financing | 5.09M | 6.9M | 258k | 803k | 1.48M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -18.9M | -31.2M | -66.76M | -40.08M | -59.27M |
| Investing | -96k | -917k | -66.48M | -199k | -87.18M |
| Financing | 8.61M | 408.51M | 614k | 190.73M | 6.9M |
| Market Cap | 563.5M |
| Price to Earnings Ratio | -22.18 |
| Price to Sales Ratio | 41.87k |
| Price to Cash Ratio | 16.99 |
| Price to Book Ratio | 5.23 |
| Dividend Yield | - |
| Shares Outstanding | 96M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 3.78 (61.46%) |
| Company Name | Silverback Therapeutics Inc |
| Address |
108 w. 13th street wilmington, delaware 19801 |
| Website | https://ars-pharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
